

## The preparatory documents for the Annual General Shareholder Meeting on 28 May 2015 have been made available

**Gosselies, Belgium, 28 April 2015** — **BONE THERAPEUTICS**, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, informs its shareholders that the Annual General Meeting will be held on 28 May 2015 at 4pm at 37 Rue Auguste Piccard, 6041 Gosselies, Belgium.

The notice for the meeting, including the agenda of the day as well as the motions too vote, have been published in the Belgian Official Gazette and L'Echo on 28 April 2015.

The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: [www.bonetherapeutics.com](http://www.bonetherapeutics.com), under the section Investors / Shareholders meeting, in compliance with the applicable law and regulations. It is also possible to receive the documents without charge upon simple request by email to [investorrelations@bonetherapeutics.com](mailto:investorrelations@bonetherapeutics.com) or by telephone on +32 (0)2 529 59 90. Finally, the documents are available at the Company's headquarters: 37 Rue Auguste Piccard, 6041 Gosselies, Belgium.

**-Ends-**

### About Bone Therapeutics

*Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.*

*PREOB<sup>®</sup>, Bone Therapeutics' autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB<sup>®</sup>, its allogeneic "off-the-shelf" bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops novel product candidates.*

*Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics' regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at [www.bonetherapeutics.com](http://www.bonetherapeutics.com).*

### For more information, please contact:

**Bone Therapeutics SA**

Tel: +32 (0)2 529 59 90

Enrico Bastianelli, Chief Executive Officer/ Wim  
Goemaere, Chief Financial Officer

[investorrelations@bonetherapeutics.com](mailto:investorrelations@bonetherapeutics.com)

**For Belgium and International Media  
Enquiries**

**Consilium Strategic Communications**

Tel: +44 (0) 20 3709 5701

Amber Bielecka, Mary-Jane Elliott, Jessica  
Hodgson and Lindsey Neville

[bonetherapeutics@consilium-comms.com](mailto:bonetherapeutics@consilium-comms.com)

**For French Media and Investor Enquiries**

**NewCap Investor Relations & Financial  
Communications**

Tel: + 33 (0)1 44 71 94 94

Pierre Laurent and Antoine Denry

[bone@newcap.fr](mailto:bone@newcap.fr)